Cystic fibrosis digest – 2021 Cystic fibrosis digest – 2021 ENaCs – Updates from Arrowhead and Enterprise Therapeutics ARO-ENaC (RNAi) – Arrowhead Pharmaceuticals Arrowhead Pharmaceuticals voluntarily paused AROENaC1001, a Phase 1/2 clinical study of ARO-ENaC Regulatory agencies, institutional review boards, […]
Cystic fibrosis digest – 2021 Cystic fibrosis digest – 2021 Eloxx Pharmaceuticals enrollment update ELX-02 (Eukaryotic ribosomal selective glycoside) – Eloxx Pharmaceuticals Trial details: Eloxx Phase 2 program, Cystic Fibrosis NCT04135495 NCT04126473 N=8 N=16 Locations: US Locations: Australia, Germany, Israel […]
Cystic fibrosis digest – 2021 Cystic fibrosis digest – 2021 Preclinical data was presented at the 44th European Cystic Fibrosis Conference (ECFS) RCT223 (tRNA) & RTX0001 (mRNA) – ReCode Therapeutics RNA-based molecular therapy program for cystic fibrosis (CF) was delivered […]
